12 Month Price Forecast For PGEN
Distance to PGEN Price Forecasts
PGEN Price Momentum
🤔 Considering Precigen (PGEN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 9:06 PM UTC
PGEN Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, PGEN has a consensus that is bullish. The median price target is $5.00, with forecasts ranging from $4.00 to $7.00. Currently, there are 4 Buy ratings, 0 Hold ratings, and 1 Sell ratings.
With PGEN currently trading at $1.18, the median price forecast suggests a 323.7% upside. The most optimistic forecast comes from Jason Butler at JMP Securities, projecting a 493.2% upside, while Swayampakula Ramakanth at HC Wainwright & Co. provides the most conservative target, suggesting a 239.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PGEN Analyst Consensus
PGEN Price Target Range
Latest PGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 14, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $5.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $4.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $4.00 |
| Aug 15, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $7.00 |
| Jun 4, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jun 3, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $10.00 |
| May 15, 2024 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $0.00 |
| May 15, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $7.00 |
| May 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Mar 22, 2024 | JP Morgan | Brian Cheng | Underweight | Downgrade | $0.00 |
| Mar 20, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jun 5, 2023 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| May 23, 2023 | JP Morgan | Brian Cheng | Neutral | Initiates | $0.00 |
| May 11, 2023 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| Mar 7, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Mar 7, 2023 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| Jan 30, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Maintains | $10.00 |
Stocks Similar to Precigen Inc
The following stocks are similar to Precigen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Precigen Inc (PGEN) Financial Data
Precigen Inc has a market capitalization of $345.59M with a P/E ratio of -2.9x. The company generates $4.39M in trailing twelve-month revenue with a 1.7% profit margin.
Revenue growth is -59.4% quarter-over-quarter, while maintaining an operating margin of -3,667.5% and return on equity of -129.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Precigen Inc (PGEN) Company Overview
About Precigen Inc
Develops precision gene and cell therapies.
Precigen, Inc. operates as a biopharmaceutical company focused on developing innovative gene and cell therapies. The company generates revenue through its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, which target various diseases. By conducting clinical trials and advancing its therapeutic programs, the company aims to commercialize its treatments and secure partnerships with healthcare organizations.
Precigen is engaged in multiple clinical trials for its products, targeting cancers and autoimmune disorders, with several programs at advanced stages. The company also offers proprietary tools like the UltraPorator for electroporation, enhancing its research capabilities. Founded in 1998 and headquartered in Germantown, Maryland, it rebranded from Intrexon Corporation in 2020.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
202
CEO
Dr. Helen Sabzevari MPH, Ph.D.
Country
United States
IPO Year
2019
Website
precigen.comPrecigen Inc (PGEN) Latest News & Analysis
Precigen, Inc. submitted a BLA for PRGN-2012, targeting RRP treatment. The company has $100M in cash, ensuring a runway into 2026, and estimates a market of 27,000 patients in the US.
PRGN-2012's potential FDA approval opens significant market opportunities for Precigen, targeting 27,000 RRP patients and broader HPV-related conditions, indicating strong future revenue potential.
Precigen, Inc. (Nasdaq: PGEN) announced that CEO Helen Sabzevari will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 9, 2025.
Helen Sabzevari's presentation at a major conference highlights Precigen's advancements in gene and cell therapies, potentially influencing investor sentiment and stock performance.
Precigen's stock saw an increase following the completion of a rolling FDA submission for its first potentially marketed product.
Precigen's FDA filing signals progress in bringing a new product to market, potentially boosting revenue and investor confidence, influencing stock performance positively.
Precigen, Inc. submitted a BLA for PRGN-2012, a potential first FDA-approved therapy for recurrent respiratory papillomatosis. It received Breakthrough and Orphan Drug Designations.
PRGN-2012's FDA Breakthrough and Orphan Drug designations highlight strong potential for market success, indicating significant investor interest and possible revenue growth for Precigen, Inc.
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
26 days agoPrecigen, Inc. announced a securities purchase agreement for the private placement of its 8.00% Series A Convertible Perpetual Preferred Stock.
The sale of Preferred Stock signals Precigen's strategy to raise capital, potentially impacting its growth and financial stability, which can influence stock performance and investor sentiment.
Precigen, Inc. plans a rolling BLA submission for PRGN-2012 in Q4 2024, with a potential 2025 launch. They initiated a confirmatory trial and are preparing for an end of Phase 1b meeting for PRGN-3006.
Successful FDA alignment and upcoming BLA submissions can indicate potential revenue growth for Precigen. A 2025 product launch and promising trial data may enhance investor confidence and stock performance.
Frequently Asked Questions About PGEN Stock
What is Precigen Inc's (PGEN) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Precigen Inc (PGEN) has a median price target of $5.00. The highest price target is $7.00 and the lowest is $4.00.
Is PGEN stock a good investment in 2025?
According to current analyst ratings, PGEN has 4 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for PGEN stock?
Wall Street analysts predict PGEN stock could reach $5.00 in the next 12 months. This represents a 323.7% increase from the current price of $1.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Precigen Inc's business model?
Precigen, Inc. operates as a biopharmaceutical company focused on developing innovative gene and cell therapies. The company generates revenue through its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, which target various diseases. By conducting clinical trials and advancing its therapeutic programs, the company aims to commercialize its treatments and secure partnerships with healthcare organizations.
What is the highest forecasted price for PGEN Precigen Inc?
The highest price target for PGEN is $7.00 from Jason Butler at JMP Securities, which represents a 493.2% increase from the current price of $1.18.
What is the lowest forecasted price for PGEN Precigen Inc?
The lowest price target for PGEN is $4.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 239.0% increase from the current price of $1.18.
What is the overall PGEN consensus from analysts for Precigen Inc?
The overall analyst consensus for PGEN is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $5.00.
How accurate are PGEN stock price projections?
Stock price projections, including those for Precigen Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
